December 13, 2017
Mitsubishi Tanabe Pharma Corporation
Oder made Medical Research Corporation
Trans Chromosomics Corporation
Strategic Collaboration for the Development of the Antibody Drug to Treat
Neurodegenerative Diseases including ALS
Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President &Representative Director: Masayuki Mitsuka, “MTPC”), Order made Medical Research
Corporation (Head Office: Kashiwa, Chiba; President & Representative Director:
Yasufumi Murakami, “OMR”) and Trans Chromosomics Inc. (Head Office: Yonago,Tottor; President & CEO: Mitsuo Oshimura, “TC”) announced that we have enteredinto a strategic collaboration for the development of an antibody drug to treat
neurodegenerative diseases, such as amyotrophic lateral sclerosis (「ALS」) inNovember, 2017.
OMR has established the innovative immunization method for membrane protein
antibody production 「LIMAXYS*1」, and is focusing to research antibody drugs

against target molecules that previous technology could not approach. TC hasdeveloped animals producing a fully human antibody created with its own
mammalian artificial chromosomes and has established cell-based assay systems tofind new targets for treating neurodegenerative diseases. MTPC has pharmaceuticalproducts edaravone (product name in Japan; Radicut; product name in US:Radicava) was approved for an indication of ALS not only in Japan June, 2015, butalso in the U.S. in May, 2017. According to a report*2, global ALS patients will

increase over the next 25 years, therefore MTPC promotes research anddevelopment of new therapeutic drugs against ALS and neurodegenerativediseases.
This collaborative research program is based on the target molecule related with theprogression of ALS that OMR and TC have discovered together. OMR and TC will
work collaboratively to obtain fully human antibody candidates against the target
molecule and MTPC will be responsible for the pre-clinical research to evaluatethem.
We will continue working to contribute to patients’ health by developing innovative
drugs that address unmet medical needs with next-generation antibody drugtechnology.

1/3

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department
Media contacts: TEL:+81 6 6205 5119
Investor contacts: TEL:+81 6 6205 5110
Oder made Medical Research Corporation
Furukawa: Tel:+81 4 7157 4530
Email:office@omr.co.jp
Trans Chromosomics Corporation
Takehara: Tel:+81 859 30 3494
Email:stakehara@trans-chromo.com<Reference>
About LIMAXYS*1
Most of membrane proteins have small extracellular domain and contains manyhydrophobic amino acids. As preparation of antigen is very difficult in suchmembrane proteins, the numbers of the suitable target for therapeutic antibodies
are limited (20 targets out of 5600 membrane proteins). Antibody generation waspossible only for the targets which have large external cellular domain. OMR Inc. has
successfully developed a novel immunization method (LIMAXYS method) usinghighly metastatic tumor cell line for immunization. Efficient immune response isinduced in the process of metastasis of the cell line which is expressing target
molecules in cellular membrane after implantation into mouse. By the use of thismethod, generation of antibodies against all kinds of membrane proteins has beenenabled. The patents of the LIMXYS method have been issued in US and Japan.
According to a report*2
Nat Commun. 2016;7:12408
About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma, which was founded in 1678, has its headquarters inDoshomachi, Osaka, which is the birthplace of Japan’s pharmaceutical industry.
With business centered on ethical pharmaceuticals, Mitsubishi Tanabe Pharma is awell-established company and has the longest history of any listed company inJapan. [i] In accordance with the corporate philosophy of “contributing to thehealthier lives of people around the world through the creation of pharmaceuticals,”
the Company formulated the key concept of Open Up the Future under theMedium-Term Management Plan 2016-2020. Through the discovery of drugs that2/3

address unmet medical needs, centered on its priority disease areas —autoimmune diseases, diabetes and kidney diseases, central nervous systemdiseases, and vaccines — Mitsubishi Tanabe Pharma will strive to contribute to thehealth of patients around the world. MTPC is the parent company of MTPA and thelicense holder of RADICAVA.
http://www.mt-pharma.co.jp/.
About Order-made Medical Research Inc.
Order-made Medical Research Inc., a biotech company focusing onto research anddevelopment of therapeutic antibody, was founded in 2012. Antibody generation
was possible only for the target which have large external cellular domain because of
the difficulty of preparation of antigen in membrane proteins. By successful
development of the LIMAXYS method, OMR is now able to produce antibodies
against all of membrane proteins. OMR is also pursuing the breakthrough in the fieldof therapeutic nucleic acid. OMR’s goal is to provide remarkable biologics for unmet
medical needs and to contribute to the health of all human being.
About Trans Chromosomics Inc.
TC Inc. was established in Yonago, Tottori prefecture in 2014 as a venture fromUniversity of Tottori University utilizing the world's most leveraging cutting edge
chromosome engineering technology. A novel artificial chromosome (NAC)
composed of a centromere and a telomere of a natural chromosome is capable ofcarrying a huge genome of several mega-bases or more, and is stable as one newchromosome in animal cells. It can be transmitted to descendants by mating of Tc(Trans chromosomic) animals. We contribute to people's living and health byapplying innovative chromosome engineering technology mainly on thedevelopment of "fully human antibody-producing mouse/rat" and "mouse/rat withgenetic rare disease " to medical treatment and drug discovering widely.
http://trans-chromo.wixsite.com/trans-chromosomicsAbout

3/3